Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2018 from OUS - Section for Preventive Cardiology
10 publications found
Dietary intake and blood concentrations of antioxidants and the risk of cardiovascular disease, total cancer, and all-cause mortality: a systematic review and dose-response meta-analysis of prospective studies
Am J Clin Nutr, 108 (5), 1069-1091
DOI 10.1093/ajcn/nqy097, PubMed 30475962
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial
JAMA Intern Med, 178 (5), 622-631
DOI 10.1001/jamainternmed.2018.0397, PubMed 29630702
Inflammatory and Cholesterol Risk in the FOURIER Trial
Circulation, 138 (2), 131-140
DOI 10.1161/CIRCULATIONAHA.118.034032, PubMed 29530884
Exploring the effect of a lifestyle intervention on cancer risk: 43-year follow-up of the randomized Oslo diet and antismoking study
J Intern Med, 284 (3), 282-291
DOI 10.1111/joim.12765, PubMed 29790221
Prevalence of diabetes before and after first diagnosis of coronary artery disease
Tidsskr Nor Laegeforen, 138 (5)
DOI 10.4045/tidsskr.17.0539, PubMed 29513466
Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial
JAMA Cardiol, 3 (8), 749-753
DOI 10.1001/jamacardio.2018.1533, PubMed 29898218
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Clin Cardiol, 41 (10), 1281-1288
DOI 10.1002/clc.23055, PubMed 30125052
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER
Circulation, 138 (8), 756-766
DOI 10.1161/CIRCULATIONAHA.118.034309, PubMed 29626068
Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation
Commun Biol, 1, 68
DOI 10.1038/s42003-018-0068-9, PubMed 30271950
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Lancet, 392 (10155), 1311-1320
DOI 10.1016/S0140-6736(18)31652-0, PubMed 30293769